<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02212015</url>
  </required_header>
  <id_info>
    <org_study_id>GISG-06</org_study_id>
    <nct_id>NCT02212015</nct_id>
  </id_info>
  <brief_title>Evaluation of Votrient in Angiosarcoma</brief_title>
  <acronym>EVA</acronym>
  <official_title>Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HELIOS Klinikum Berlin-Buch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum der Universitaet Muenchen, Grosshadern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label phase II trial investigating the efficacy and safety of the investigational
      combination of pazopanib and paclitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label phase II trial investigating the efficacy and safety of the investigational
      combination of pazopanib and paclitaxel.This multi-center, open-label, prospective, single
      arm phase II study was designed to evaluate the clinical efficacy and safety of the
      experimental combination of pazopanib with paclitaxel in the treatment of patients with
      advanced or metastatic angiosarcoma.The safety evaluations (physical examination, laboratory
      checks as defined in protocol, toxicity/adverse event assessment according Eastern
      Cooperative Oncology Group version 4.0) are scheduled every cycle at day 1, 8, 15 and 29 (=
      day 1 of the next cycle).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of progression-free survival</measure>
    <time_frame>6 Month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 weeks after EOS of last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>8 weeks during first 6 month then 12 weeks follow-up period until progression or death</time_frame>
    <description>Measurable skin lesions will be evaluated clinically and documented photographically, all other target lesions will be evaluated radiologically by CT or MRI according to RECIST Version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>30 days after EOS of last patient</time_frame>
    <description>Number of patients in which adverse events occur during treatment according to Common Toxicity Criteria for Adverse Effects , Version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Angiosarcoma</condition>
  <arm_group>
    <arm_group_label>Pazopanib + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib + Paclitaxel</intervention_name>
    <description>pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.</description>
    <arm_group_label>Pazopanib + Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must provide written informed consent prior to performance of study-specific
             procedures or assessments and must be willing to comply with treatment and follow-up.
             Note: Procedures conducted as part of the subject's routine clinical management (e.g.,
             blood count, imaging studies) and obtained prior to signing informed consent may be
             utilized for screening or baseline purposes provided these procedures are conducted as
             specified in the protocol.

          -  Age ≥ 18 years

          -  Life expectancy &gt; 3 months

          -  Ability to swallow tablets

          -  Histological confirmed angiosarcoma, primary and secondary angiosarcoma (e.g.
             radiation-induced or angiosarcoma in chronical lymphedema) are eligible.

          -  Tumor must be locally advanced (unresectable) or metastatic. A progression must be
             documented within a 6-month period prior to screening.

          -  Eastern Cooperative Oncology Group performance status ≤ 2

          -  At least one measurable skin lesion or one measurable radiological (CT or MRI) target
             lesion (RECIST 1.1)

          -  Adequate organ system function as described in protocol

          -  A female is eligible to enter and participate in this study if she is either of non
             childbearing potential (defined in protocol) or childbearing potential with negative
             pregnancy test within 2 weeks prior to the first dose of study drug and agrees to use
             adequate contraception (as defined in protocol) during the study and for 30 days after
             the last dose of study drug.

          -  All sexually active male patients must agree to use adequate methods of birth control
             (see protocol) throughout the study and for 30 days after the last dose of study drug.

        Exclusion Criteria:

          -  Patients who need an active treatment for another malignant disease other than
             angiosarcoma

          -  Prior treatment with taxane within the last 12 months before study entry

          -  History or clinical evidence of central nervous system (CNS) metastases or
             leptomeningeal sarcomatosis.(see protocol)

          -  Clinically significant gastrointestinal abnormalities that may increase the risk for
             gastrointestinal bleeding (see protocol)

          -  Clinically significant gastrointestinal abnormalities that may affect absorption of
             investigational product (see protocol)

          -  Presence of uncontrolled infection

          -  QT prolongation interval (QTc) &gt; 480 msec.

          -  Clinically significant cardiovascular disorders within the past 6 months

          -  Major surgery or trauma within 28 days prior to first dose of investigational product
             and/or presence of any non-healing wound, fracture, or ulcer

          -  Poorly controlled hypertension (see protocol)

          -  Evidence of active bleeding or bleeding diathesis

          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels

          -  Uncontrolled seizures, disorders of the CNS or psychiatric disorders which may put
             patient safety at risk, prevent giving informed consent or impact the patient's
             compliance with the use of study medication

          -  Women who are pregnant or breast feeding

          -  Patients who are not able or not willing to interrupt the intake of medications that
             are not allowed according to study protocol for at least 14 days before start of study
             medication and for the whole study period

          -  Chemotherapy or radiotherapy within 14 days before start of study medication

          -  Any ongoing toxicity from prior anti-cancer therapy that is &gt; grade 1 and/or that is
             progressing in severity, except alopecia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hohenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Centre Mannheim and Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Hohenberger, MD</last_name>
    <phone>++49621383</phone>
    <phone_ext>3433</phone_ext>
    <email>studien@gisg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Reichardt, MD</last_name>
    <phone>++49309401</phone>
    <phone_ext>14852</phone_ext>
    <email>annette.reichardt@helios-kliniken.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinik Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Eisterer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wolfgang Eisterer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferdinand Ploner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ferdinand Ploner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Brodowicz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Brodowicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Reichardt, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Daniel Pink, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Peter Reichardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Schuler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Markus Schuler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Bauer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sebastian Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nils Thoennissen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nils Thönnissen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktor Grünwald, MD</last_name>
    </contact>
    <investigator>
      <last_name>Viktor Grünwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Center Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Hohenberger, MD</last_name>
      <phone>0049621383</phone>
      <phone_ext>3433</phone_ext>
      <email>studien@gisg.de</email>
    </contact>
    <contact_backup>
      <last_name>Bernd Kasper, MD</last_name>
      <phone>0049621383</phone>
      <phone_ext>3433</phone_ext>
      <email>studien@gisg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Hohenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München Campus Großhadern</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Lindner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lars Lindner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.gisg.de</url>
    <description>German Interdisciplinary Sarcoma Group</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

